|
|
|
市場調查報告書
VEGF抑制劑：治療適應症與預後性生物標記, 2011年
VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011
|
VEGF抑制劑：治療適應症與預後性生物標記, 2011年 是由出版商BioPharm Reports (Technology and Markets Ltd)在2011年10月所出版的。
這份英文市場調查報告書包含97 Pages 價格從美金1520起跳。
CEGF（血管内皮細胞増生因素）負責血管形成這項重要的任務並被廣泛研究。VEGF是抗體或激酶抑制劑所使用的方法，抗血管新生療法為大腸癌與非小細胞肺癌等多種癌症的標準治療法。
本報告針對VEGF抑制劑概要與預後性生物標記進行各癌症種類分類潛在可能生物標記調查分析，目錄介紹如下。
摘要整理
第1章 背景
- VEGF抑制
- Bevacizumab
- 生物標記
- 關於本報告
第2章 大腸癌：接受Bevacizumab治療患者潛在可能生物標記
第3章 乳癌：接受Bevacizumab治療患者潛在可能生物標記
第4章 腎癌：接受Bevacizumab治療患者潛在可能生物標記
第5章 卵巢癌：接受Bevacizumab治療患者潛在可能生物標記
第6章 肺癌：接受Bevacizumab治療患者潛在可能生物標記
第7章 肝癌：接受Bevacizumab治療患者潛在可能生物標記
第8章 其他癌症：接受Bevacizumab治療患者潛在可能生物標記
第9章 考察
- 概要
- 結腸直腸癌
- 乳癌
- 腎癌
- 卵巢癌
- 肺癌
- 肝癌
- 其他
- 結論
圖表
Abstract
Vascular Endothelial Growth Factor (VEGF), which plays an important role in
angiogenesis, has been extensively studied and over-expression is seen in many
cancers. Today, VEGF is targeted using antibodies and tyrosine kinase
inhibitors, and antiangiogenic therapy is a standard treatment for many
cancers, including colorectal and non-small cell lung cancer.
While VEGF inhibitors such as bevacizumab (Avastin®) provide valuable
treatment options, these benefits are not seen in all patients and cancer
types. Today, there is an urgent need for predictive biomarkers to enable
those patients most likely to benefit from VEGF inhibition, to be identified.
This report provides a review of findings to date on biomarkers
associated with the use bevacizumab (Avastin®); both therapy-indicating and
prognostic.
The identification of therapy-indicating and prognostic biomarkers relating to
antiangiogenic therapy is in its early stages, however important advances have
been made. This report identifies the latest findings on ten different cancers
and includes an evaluation of candidate biomarkers as a basis for interpreting
patient outcomes according to RECIST criteria, and evaluates existing
bevacizumab-containing treatments and drug combinations.
Key content:
- A comprehensive review of clinical studies that have identified biomarkers
that are either therapy-indicating in respect of bevacizumab (Avastin®) or
indicative of patient prognosis
- Biomarkers identified or further evaluated in the last three years, up
until October 2011. From a background of extensive research on bevacizumab
(Avastin®) and VEGF-related biomarkers, the most important findings have been
identified for their significance and value to patients and in designing
clinical trials
- Covering more than ten cancers including colorectal, ovarian, renal,
breast, pancreatic, prostate, lung and liver cancers
- Findings based on clinical trial findings including patient numbers,
statistics and RECIST criteria
- Studies indicate drug type associations together with comparative therapies
- Descriptions and explanation of all biomarkers identified roteins,
genotypes, imaging etc)
- Biomarker associations are categorised according to three broad criteria,
namely “positive-therapy-indicating” (response, improved response,
improved outcome or prognosis), “non-therapy-indicating” (no
differences in tumour response, outcome or prognosis) and
“negative-therapy-indicating” (adverse events, poor outcome or
prognosis)
Table of Contents
Executive Summary
Chapter-1: Background
- 1.1. VEGF Inhibition
- 1.2. Bevacizumab
- 1.3. Biomarkers
- 1.4. This Report
Chapter-2: Colorectal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies
- Summary
- 2.1. Introduction
- 2.2. Glycoprotein
- 2.3. Protein
- 2.4. Protein
- 2.5. Cells
- 2.6. Genetic
- 2.7. Physical
- 2.8. Genetic
- 2.9. Protein
- 2.10. Proteins
- 2.11. Proteins and Genetic
- 2.12. Image
- 2.13. Proteins
- 2.14. Protein
Chapter-3: Breast Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies
- Summary
- 3.1. Introduction
- 3.2. Protein
- 3.3. Protein
- 3.4. Protein
- 3.5. Protein
- 3.6. Protein
- 3.7. Genetic
- 3.8. Protein
Chapter-4: Renal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies
- Summary
- 4.1. Introduction
- 4.2. Image
- 4.3. Protein
- 4.4. Physical
- 4.5. Protein
- 4.6. Body Characteristic
Chapter-5: Ovarian Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies
- Summary
- 5.1. Introduction
- 5.2. Proteins
- 5.3. Proteins
- 5.4. Proteins
- 5.5. Proteins
Chapter-6: Lung Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies
- Summary
- 6.1. Introduction
- 6.2. Physical Parameter
- 6.3. Protein
- 6.4. Genetic
- 6.5. Protein
Chapter-7: Liver Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies
- Summary
- 7.1. Introduction
- 7.2. Protein
- 7.3. Image
Chapter-8: Other Cancers: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies
- Summary
- 8.1. Introduction
- 8.2. Proteins
- 8.3. Proteins
- 8.4. Protein
- 8.5. Protein
- 8.6. Physical
- 8.7. Physical
- 8.8. Physical
Chapter-9: Discussion
- 9.1. Overview
- 9.2. Colorectal Cancer
- 9.3. Breast Cancer:
- 9.4. Renal Cancer:
- 9.5. Ovarian Cancer
- 9.6. Lung Cancer
- 9.7. Liver Cancer
- 9.8. Other Cancers
- 9.9. Conclusions
Tables
- Table 2.1: Candidates biomarkers identified in colorectal cancer patients
receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type,
drug therapies)
- Table 3.1: Candidates biomarkers identified in breast cancer patients
receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type,
drug therapies)
- Table 4.1: Candidates biomarkers identified in renal cancer patients
receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type,
drug therapies)
- Table 5.1: Candidates biomarkers identified in ovarian cancer patients
receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type,
drug therapies)
- Table 6.1: Candidates biomarkers identified in lung cancer patients
receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type,
drug therapies)
- Table 7.1: Candidates biomarkers identified in liver cancer patients
receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type,
drug therapies)
- Table 8.1: Candidates biomarkers identified in other cancer patients
receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type,
drug therapies)
- Table 9.1: Protein candidate biomarkers identified in cancer patients
receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type,
drug therapies)
- Table 9.2: Genetic candidate biomarkers identified in cancer patients
receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type,
drug therapies)
- Table 9.3: Image-based candidate biomarkers identified in cancer patients
receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type,
drug therapies)
- Table 9.4: Other candidate biomarkers identified in cancer patients
receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type,
drug therapies)
Figures
- Figure 9.1: Candidate biomarkers types identified in cancer patients
receiving bevacizumab-containing therapies
- Figure 9.2: Cancer types evaluated for biomarkers identified in cancer
patients receiving bevacizumab-containing therapies
- Figure 9.3: Author countries (identified in this report) of cancers
evaluated for biomarkers identified in cancer patients receiving
bevacizumab-containing therapies
|
 |
